文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

应用无监督聚类分析推导2022年西班牙危重型COVID-19患者的临床表型及与死亡风险相关的危险因素

Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain.
PubMed 文献 · Crit Care · 2021-02-15
一句话结论在西班牙63个ICU的2022例危重型COVID-19患者中,无监督聚类识别出3种临床表型,A、B、C表型的ICU粗死亡率分别为20.3%、25%和45.4%。

该研究为前瞻性、多中心、观察性研究,纳入西班牙63个ICU收治的2022例确诊COVID-19并急性呼吸衰竭的危重患者,采用无监督聚类分析推导临床表型,并用广义线性模型分析ICU死亡危险因素。共识别出3种表型:A(轻度)537例(26.7%)、B(中度)623例(30.8%)、C(重度)857例(42.5%),ICU粗死亡率分别为20.3%、25%和45.4%。全人群与各表型间的ICU死亡危险因素及模型性能不同,提示「一刀切」模型在实践中的应用可能受限。

要点

  • 2022例危重型COVID-19患者中ICU粗死亡率为32.6%,C(重度)表型占42.5%、ICU粗死亡率45.4%。
  • A(轻度)表型537例(26.7%)、B(中度)表型623例(30.8%),ICU粗死亡率分别为20.3%和25%。
  • C(重度)表型以年龄>65岁、疾病严重程度高和发生休克可能性更高为特征。
  • B(中度)表型具有与A表型相似的特征,但更可能出现休克。
  • 全人群与按表型分类后,ICU死亡危险因素及模型性能不同,可能限制「一刀切」模型的应用。

适用人群与场景

  • 西班牙63个ICU收治的2022例确诊COVID-19并急性呼吸衰竭的危重患者。
  • 分析的特征包括入住ICU时的人口学和临床数据。

研究设计与关键结果

  • 研究类型:前瞻性、多中心、观察性研究,纳入西班牙63个ICU的2022例患者。
  • 人群特征:平均年龄64(IQR 5-71)岁,男性1423例(70.4%),中位APACHE II评分13(IQR 10-17)分,中位SOFA评分5(IQR 3-7)分。
  • 主要结局:ICU死亡率为32.6%。
  • 表型分布:A(轻度)表型537例(26.7%),B(中度)表型623例(30.8%),C(重度)表型857例(42.5%)。
  • 表型特征:A(轻度)表型包括年龄较轻(<65岁)、异常实验室值较少和并发症发生较少;B(中度)表型具有与A表型相似的特征但更可能出现休克;C(重度)表型以年龄较大(>65岁)、疾病严重程度高和发生休克可能性更高为特征。
  • ICU粗死亡率:A表型20.3%、B表型25%、C表型45.4%。
  • 全人群与按表型分类后,ICU死亡危险因素及模型性能不同;预后模型经过验证,性能通过准确率检验、敏感性、特异性和ROC曲线衡量。

证据类型、等级与局限

  • 证据类型:前瞻性、多中心、观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 机器学习模型识别出3种与宿主反应模式和ICU死亡率显著相关的临床表型;全人群与各临床表型间的危险因素不同,可能限制「一刀切」模型在实践中的应用(作者认为)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The identification of factors associated with Intensive Care Unit (ICU) mortality and derived clinical phenotypes in COVID-19 patients could help for a more tailored approach to clinical decision-making that improves prognostic outcomes.

METHODS: Prospective, multicenter, observational study of critically ill patients with confirmed COVID-19 disease and acute respiratory failure admitted from 63 ICUs in Spain. The objective was to utilize an unsupervised clustering analysis to derive clinical COVID-19 phenotypes and to analyze patient's factors associated with mortality risk. Patient features including demographics and clinical data at ICU admission were analyzed. Generalized linear models were used to determine ICU morality risk factors. The prognostic models were validated and their performance was measured using accuracy test, sensitivity, specificity and ROC curves.

RESULTS: The database included a total of 2022 patients (mean age 64 [IQR 5-71] years, 1423 (70.4%) male, median APACHE II score (13 [IQR 10-17]) and SOFA score (5 [IQR 3-7]) points. The ICU mortality rate was 32.6%. Of the 3 derived phenotypes, the A (mild) phenotype (537; 26.7%) included older age (< 65 years), fewer abnormal laboratory values and less development of complications, B (moderate) phenotype (623, 30.8%) had similar characteristics of A phenotype but were more likely to present shock. The C (severe) phenotype was the most common (857; 42.5%) and was characterized by the interplay of older age (> 65 years), high severity of illness and a higher likelihood of development shock. Crude ICU mortality was 20.3%, 25% and 45.4% for A, B and C phenotype respectively. The ICU mortality risk factors and model performance differed between whole population and phenotype classifications.

CONCLUSION: The presented machine learning model identified three clinical phenotypes that significantly correlated with host-response patterns and ICU mortality. Different risk factors across the whole population and clinical phenotypes were observed which may limit the application of a "one-size-fits-all" model in practice.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Rodríguez A, Ruiz-Botella M, Martín-Loeches I, et al. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. Crit Care. 2021. PMID: 33588914. doi:10.1186/s13054-021-03487-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。